Última Hora: "Dívida pública termina trimestre a valer 125,8% do PIB - PÚBLICO" Tue, 18 Sep 2018 16:54:47 GMT    "Quais as marcas mais valiosas em Portugal? - Jornal de Negócios - Portugal" Tue, 18 Sep 2018 12:00:59 GMT   "" Tue, 18 Sep 2018 17:05:09 GMT    "Clientes do Continente encontram larvas junto a latas de atum - Notícias ao Minuto (liberação de imprensa)" Tue, 18 Sep 2018 10:55:49 GMT    "Bertrand rejeita acusações de livreiros e assegura cumprimento escrupuloso da lei - Diário de Notícias - Lisboa" Tue, 18 Sep 2018 14:05:51 GMT    "João Talone. ?A EDP nasce do Estado, a EDP era o Estado. Hoje é o mau da fita? - Observador" Tue, 18 Sep 2018 15:59:55 GMT    "Vídeo de homem a barbear-se em comboio torna-se viral - Correio da Manhã" Tue, 18 Sep 2018 16:21:21 GMT    "Alfa Pendular esteve em risco de descarrilar, CP já está a investigar - PÚBLICO" Tue, 18 Sep 2018 06:13:05 GMT    "Metro e Carris admitem reforçar meios devido à manifestação de taxistas - Notícias ao Minuto (liberação de imprensa)" Tue, 18 Sep 2018 12:21:30 GMT    "Uber, Cabify, Taxify e Chaffeur Privé, quatro plataformas a operar em Portugal - Diário de Notícias - Lisboa" Tue, 18 Sep 2018 13:22:20 GMT      Para mais notícias, clique aqui.

Área de Acesso
       
       
Lembrar Sempre 
(Login BolsaPT & Canal Forex)

Queda de
--10.00 (+0.97%) SCHERING PLOUGH C - [Ticker: SGP]Gráfico SCHERING PLOUGH C  Notícias SCHERING PLOUGH C  Download de Históricos Metastock SCHERING PLOUGH C e Outros  Análise Técnica SCHERING PLOUGH C  
Última Trade368,000Range 52 Semanas[0,000 - 0,000]
Hora da Última Trade2018-09-14 - 00:00:00Price-Target 1 Ano0,000
Variação--10.00 (+0.97%)Capitalização Bolsista0
Bid / AskN/AEPS0,00
Abertura378,000PER0,00%
Máximo378,000Pagamento Dividendo
Mínimo368,000Data Ex-Dividendo
Fecho Anterior378,000Yield
Volume420Volume Médio (3m)0
Nota: Os dados podem apresentar atraso de alguns minutos.
Ver cotações de outros activos

Intraday   5 dias   1 mes   3 meses   6 meses   1 ano   2 anos   5 anos   10 anos            Use este gráfico no seu website!
Gráfico de SCHERING PLOUGH C -  [Ticker: SGP]
Mudar para Gráfico de Análise Técnica Interactiva de SCHERING PLOUGH C

Últimos 10 Tópicos no Fórum sobre SCHERING PLOUGH C:
Não foram encontrados tópicos sobre SCHERING PLOUGH C [SGP], mas aconselha-se pesquisa no Fórum por tópicos relacionados com SCHERING PLOUGH C.

 Notícias sobre SCHERING PLOUGH C [SGP]:   (ordenadas por relevância)

Marketing magazine Australia

Making sense out of madness ? how this marketer is making it look ...
Marketing magazine Australia
The client list was vast, with more than 60 charities and pharmaceutical companies across the UK and Canada, including WWF, Oxfam and Schering-Plough. But she realised this wasn't the right path for her. ?I wasn't interested in making something appealing.


Reuters

Keytruda sales power Merck to quarterly beat
Reuters
(Reuters) - Drugmaker Merck & Co (MRK.N) reported better-than-expected first-quarter earnings on Tuesday, helped by a more than 150 percent rise in sales of blockbuster cancer drug Keytruda.


The Economist

A pharmaceutical firm bets big on a cancer drug
The Economist
Merck's merger with another pharma firm, Schering-Plough, in 2009, had brought it an obscure new cancer drug. At first Merck's scientists were unimpressed and relegated the drug to a list of assets to be licensed out. There was widespread scepticism at ...


Merck, Schering-Plough set to complete merger
Reuters
NEW YORK (Reuters) - Merck & Co (MRK.N) and Schering-Plough Corp SGP.N said their $41.1 billion merger will be completed later on Tuesday, marking the close of the second huge deal in the pharmaceutical industry in recent weeks. Pfizer Inc (PFE.


The Pharmaceutical Journal

Hepatitis C: tackling the silent killer
The Pharmaceutical Journal
1997: The first alpha interferon, Schering-Plough's Intron A (interferon alpha-2B), is approved for treatment of hepatitis C in the UK. 1999: European blood services begin screening blood with nucleic acid amplification testing (NAT), because it ...


Forbes

What You Should Know About Ken Frazier, The CEO Who Just Quit ...
Forbes
Kenneth C. Frazier, the chairman and chief executive of the U.S. drug maker Merck, resigned from President Donald Trump's American Manufacturing Council on Monday morning, saying in a statement, ?As CEO of Merck and as a matter of personal conscience ...

e mais »

Farmacêuticas Merck e Schering iniciam fusão das operações ...
O Globo
São Paulo - A Merck Sharp & Dohme e a Schering-Plough começam a operar a partir desta quarta-feira como uma única empresa. A nova companhia será conhecida globalmente como MSD (a empresa irá operar como Merck somente nos Estados Unidos e ...

e mais »

In Vivo

Bristol/Medarex: A Transformational Acquisition Rooted In ...
In Vivo
Bristol's $2.4 billion buyout of Medarex in 2009 yielded value equivalent or greater to that realized in larger M&A transactions signed that year, such as Pfizer/Wyeth, Merck/Schering-Plough and Roche/Genentech. The deal made BMS a leader in ...


GlobeNewswire (press release)

Esperion Announces the Appointment of Jeffrey Berkowitz to Board ...
GlobeNewswire (press release)
We are confident Jeff will provide important contributions to help us deliver on the promise of bringing our complementary, oral LDL-C lowering therapies to the millions of patients who are inadequately treated with, or unable to gain access to ...

e mais »

Dividend investors: You need to watch out for this
Stansberry Churchouse Research (blog)
With this strategy, Anne had amassed a US$22 million fortune by the time she passed away in 1995 ? including US$7.5 million worth of pharmaceutical company Schering-Plough shares and US$720,000 worth of Coca-Cola shares. Anne's story is just one ...


TCTMD

SECURE-PCI Comes Up Short for Statin Preloading in ACS Patients
TCTMD
In PROVE-IT, for example, high-intensity statin therapy started within 7 days of ACS showed a clinical benefit, as did early treatment with ezetimibe (Zetia; Merck/Schering-Plough) in IMPROVE-IT. ?But that still leaves the early window,? she added ...

e mais »

Merck to buy Schering-Plough for $41.1 billion
MarketWatch
Before the opening bell Monday, the two major drugmakers said they have agreed to a merger that calls for Schering-Plough SGP, -4.89% shareholders to receive $10.50 in cash and 0.5767 in Merck MRK, +0.63% stock for each share of Schering-Plough.


Merck, Schering-Plough to complete merger Tuesday
MarketWatch
MRK, -0.53% and Schering-Plough Corp. SGP, -2.65% said they will complete their $41 billion merger after the market's close on Tuesday. As a result, Schering-Plough's stock will cease trading later Tuesday. The combined company will be known as Merck, ...

e mais »

RTE.ie

Animal medicines company purchases Rathdrum site
RTE.ie
The world's largest manufacturer of animal medicines and vaccines has bought the former MSD pharmaceutical plant in Rathdrum, Co Wicklow. US-based company Zoetis, which already operates two sites in Ireland, confirmed to RTÉ News this evening it has ...

e mais »

CNNMoney.com

Merck and Schering-Plough in $41B merger
CNNMoney.com
... and Swiss drugmaker Roche Holding AG continues to pursue a $40 billion hostile bid of Genentech Inc. (DNA). Shares of Merck (MRK, Fortune 500) fell about 11% and Schering-Plough (SGP, Fortune 500) shares were up about 11% in premarket trading.
Merck to Buy Rival for $41 BillionWall Street Journal

todos os 2.448 artigos de notícias »
Para mais notícias sobre SCHERING PLOUGH C clique aqui:
Notícias de SCHERING PLOUGH C

Largura do Site:

 Imagem de Fundo:

Copyright@1998-2018 - BolsaPT.com, todos os direitos reservados.
Fórum de Bolsa Cotações de Bolsa Notícias de Bolsa Chat de Bolsa Disclaimer Recursos para Webmasters